{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:26:56Z","timestamp":1787308016196,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114911","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:58:51Z","timestamp":1787306331000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Features and Prognostic Impact of Human Epidermal Growth Factor Receptor 2-Low Status in Early-Stage Breast Cancer: A Single-Center Cohort Hormone Receptor-Stratified Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Mai A","family":"Abdelazez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"M. Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashayer","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Moharram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou CM","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al.. Molecular portraits of human breast tumours. Nature. 2000, 406:747-52. 10.1038\/35021093","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini F","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al.. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021, 7:1. 10.1038\/s41523-020-00208-2","journal-title":"NPJ Breast Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert C","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, et al.. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021, 22:1151-61. 10.1016\/S1470-2045(21)00301-6","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino P","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al.. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020, 38:1951-62. 10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini M","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, et al.. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022, 7:100591. 10.1016\/j.esmoop.2022.100591","journal-title":"ESMO Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S366122","article-title":"HER2-low breast cancer: current landscape and future prospects","volume":"15","author":"Shirman Y","year":"2023","unstructured":"Shirman Y, Lubovsky S, Shai A. HER2-low breast cancer: current landscape and future prospects. Breast Cancer (Dove Med Press). 2023, 15:605-16. 10.2147\/BCTT.S366122","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040644","article-title":"HER2-low breast cancer-current knowledge and future directions","volume":"61","author":"Shaaban AM","year":"2025","unstructured":"Shaaban AM, Kaur T, Provenzano E. HER2-low breast cancer-current knowledge and future directions. Medicina (Kaunas). 2025, 61:10.3390\/medicina61040644","journal-title":"Medicina (Kaunas)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.092","article-title":"A nationwide study on HER2-low breast cancer in South Korea: its incidence of 2022 real world data and the importance of immunohistochemical staining protocols","volume":"56","author":"Kim MC","year":"2024","unstructured":"Kim MC, Cho EY, Park SY, et al.. A nationwide study on HER2-low breast cancer in South Korea: its incidence of 2022 real world data and the importance of immunohistochemical staining protocols. Cancer Res Treat. 2024, 56:1096-104. 10.4143\/crt.2024.092","journal-title":"Cancer Res Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39372-3","article-title":"Clinicopathological characteristics of HER2-low breast cancer: a retrospective study","volume":"13","author":"Yang M","year":"2023","unstructured":"Yang M, Sun J, Liu L, Kong X, Lin D, Zhou H, Gao J. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci Rep. 2023, 13:12382. 10.1038\/s41598-023-39372-3","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100164","article-title":"Incidence, clinicopathologic features, HER2 fluorescence in situ hybridization profile, and Oncotype DX results of human epidermal growth factor receptor 2-low breast cancers: experience from a single academic center","volume":"36","author":"Hu Y","year":"2023","unstructured":"Hu Y, Jones D, Zhao W, Tozbikian G, Wesolowski R, Parwani AV, Li Z. Incidence, clinicopathologic features, HER2 fluorescence in situ hybridization profile, and Oncotype DX results of human epidermal growth factor receptor 2-low breast cancers: experience from a single academic center. Mod Pathol. 2023, 36:100164. 10.1016\/j.modpat.2023.100164","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP4A7KTAYHZSOE","article-title":"Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance","volume":"140","author":"Lambein K","year":"2013","unstructured":"Lambein K, Van Bockstal M, Vandemaele L, et al.. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol. 2013, 140:561-6. 10.1309\/AJCP4A7KTAYHZSOE","journal-title":"Am J Clin Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00964-8","article-title":"HER2-low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast","volume":"18","author":"Bardia A","year":"2023","unstructured":"Bardia A, Viale G. HER2-low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast. Target Oncol. 2023, 18:313-9. 10.1007\/s11523-023-00964-8","journal-title":"Target Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022, 387:9-20. 10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano F","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction?. Curr Oncol Rep. 2022, 24:809-17. 10.1007\/s11912-022-01266-4","journal-title":"Curr Oncol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11421-0","article-title":"Clinicopathological features and prognosis of patients with HER2-low breast cancer","volume":"23","author":"Yang X","year":"2023","unstructured":"Yang X, Li Y, Lu X, Ren X, Hua B. Clinicopathological features and prognosis of patients with HER2-low breast cancer. BMC Cancer. 2023, 23:914. 10.1186\/s12885-023-11421-0","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.774577","article-title":"In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China","volume":"11","author":"Li Y","year":"2021","unstructured":"Li Y, Abudureheiyimu N, Mo H, et al.. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China. Front Oncol. 2021, 11:774577. 10.3389\/fonc.2021.774577","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153774","article-title":"Targeted approaches to HER2-low breast cancer: current practice and future directions","volume":"14","author":"Lai HZ","year":"2022","unstructured":"Lai HZ, Han JR, Fu X, Ren YF, Li ZH, You FM. Targeted approaches to HER2-low breast cancer: current practice and future directions. Cancers (Basel). 2022, 14:10.3390\/cancers14153774","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112824","article-title":"HER2-low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto E","year":"2021","unstructured":"Agostinetto E, Rediti M, Fimereli D, et al.. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021, 13:10.3390\/cancers13112824","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02047-0","article-title":"Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer","volume":"9","author":"Yi Z","year":"2024","unstructured":"Yi Z, Feng K, Lv D, Guan Y, Shao Y, Ma F, Xu B. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct Target Ther. 2024, 9:345. 10.1038\/s41392-024-02047-0","journal-title":"Signal Transduct Target Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2481825","article-title":"ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-, ESR1-mutated, metastatic breast cancer","volume":"21","author":"Goetz MP","year":"2025","unstructured":"Goetz MP, Wander SA, Bachelot T, et al.. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol. 2025, 21:1317-24. 10.1080\/14796694.2025.2481825","journal-title":"Future Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231175440","article-title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","volume":"15","author":"Yang C","year":"2023","unstructured":"Yang C, Brezden-Masley C, Joy AA, Sehdev S, Modi S, Simmons C, Henning JW. Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Ther Adv Med Oncol. 2023, 15:17588359231175440. 10.1177\/17588359231175440","journal-title":"Ther Adv Med Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6965","article-title":"Lymph node ratio as an alternative to pN staging in node-positive breast cancer","volume":"27","author":"Vinh-Hung V","year":"2009","unstructured":"Vinh-Hung V, Verkooijen HM, Fioretta G, et al.. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009, 27:1062-8. 10.1200\/JCO.2008.18.6965","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database","volume":"9","author":"Peiffer DS","year":"2023","unstructured":"Peiffer DS, Zhao F, Chen N, et al.. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the National Cancer Database. JAMA Oncol. 2023, 9:500-10. 10.1001\/jamaoncol.2022.7476","journal-title":"JAMA Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00732-5","article-title":"Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status","volume":"11","author":"Cha CD","year":"2025","unstructured":"Cha CD, Kim KE, Kim J, et al.. Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status. NPJ Breast Cancer. 2025, 11:31. 10.1038\/s41523-025-00732-5","journal-title":"NPJ Breast Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030417","article-title":"Unique molecular alteration of lobular breast cancer: association with pathological classification, tumor biology and behavior, and clinical management","volume":"17","author":"Zhang H","year":"2025","unstructured":"Zhang H, Peng Y. Unique molecular alteration of lobular breast cancer: association with pathological classification, tumor biology and behavior, and clinical management. Cancers (Basel). 2025, 17:10.3390\/cancers17030417","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100463","article-title":"Molecular and clinical portrait of HER2-low invasive lobular carcinomas","volume":"37","author":"Djerroudi L","year":"2024","unstructured":"Djerroudi L, El Sabeh-Ayoun A, Benoist C, et al.. Molecular and clinical portrait of HER2-low invasive lobular carcinomas. Mod Pathol. 2024, 37:100463. 10.1016\/j.modpat.2024.100463","journal-title":"Mod Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02058-x","article-title":"Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study","volume":"27","author":"Van Baelen K","year":"2025","unstructured":"Van Baelen K, Nguyen HL, Richard F, et al.. Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. Breast Cancer Res. 2025, 27:106. 10.1186\/s13058-025-02058-x","journal-title":"Breast Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01519-x","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society","volume":"24","author":"Won HS","year":"2022","unstructured":"Won HS, Ahn J, Kim Y, et al.. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022, 24:22. 10.1186\/s13058-022-01519-x","journal-title":"Breast Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng X","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes (Basel). 2024, 15:10.3390\/genes15070903","journal-title":"Genes (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2 E","year":"2023","unstructured":"Nicol\u00f2 E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol. 2023, 15:17588359231152842. 10.1177\/17588359231152842","journal-title":"Ther Adv Med Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104584","article-title":"Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis","volume":"84","author":"Yang Y","year":"2025","unstructured":"Yang Y, Pan L, Zhou W, Shao Z. Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis. Breast. 2025, 84:104584. 10.1016\/j.breast.2025.104584","journal-title":"Breast"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01019-5","article-title":"HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles","volume":"35","author":"Zhang H","year":"2022","unstructured":"Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. 2022, 35:1075-82. 10.1038\/s41379-022-01019-5","journal-title":"Mod Pathol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1138","article-title":"HER2-low breast cancer: now and in the future","volume":"56","author":"Kang S","year":"2024","unstructured":"Kang S, Kim SB. HER2-low breast cancer: now and in the future. Cancer Res Treat. 2024, 56:700-20. 10.4143\/crt.2023.1138","journal-title":"Cancer Res Treat"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00901-8","article-title":"Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer","volume":"12","author":"Singareeka Raghavendra A","year":"2026","unstructured":"Singareeka Raghavendra A, Liu DD, Pasyar S, et al.. Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer. NPJ Breast Cancer. 2026, 12:10.1038\/s41523-026-00901-8","journal-title":"NPJ Breast Cancer"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli C","year":"2023","unstructured":"Molinelli C, Jacobs F, Agostinetto E, et al.. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. ESMO Open. 2023, 8:101592. 10.1016\/j.esmoop.2023.101592","journal-title":"ESMO Open"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11856","article-title":"Nomogram model of LNR predicts survival in premenopausal patients with node-positive luminal breast cancer","volume":"37","author":"Qin T","year":"2017","unstructured":"Qin T, Zeng YD, Lu Q, et al.. Nomogram model of LNR predicts survival in premenopausal patients with node-positive luminal breast cancer. Anticancer Res. 2017, 37:4575-86. 10.21873\/anticanres.11856","journal-title":"Anticancer Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2010.133","article-title":"Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer","volume":"1","author":"Nishimura R","year":"2010","unstructured":"Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010, 1:747-54. 10.3892\/etm.2010.133","journal-title":"Exp Ther Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103962","article-title":"Survival differences between HER2-0 and HER2-low-expressing breast cancer \u2212 a meta-analysis of early breast cancer patients","volume":"185","author":"Yang C","year":"2023","unstructured":"Yang C, Zhang X, Chen Y, et al.. Survival differences between HER2-0 and HER2-low-expressing breast cancer \u2212 a meta-analysis of early breast cancer patients. Crit Rev Oncol Hematol. 2023, 185:103962. 10.1016\/j.critrevonc.2023.103962","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-022-03062-9","article-title":"The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer","volume":"25","author":"Wang W","year":"2023","unstructured":"Wang W, Zhu T, Chen H, Yao Y. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer. Clin Transl Oncol. 2023, 25:1673-81. 10.1007\/s12094-022-03062-9","journal-title":"Clin Transl Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03962-4","article-title":"Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study","volume":"23","author":"Zeng Y","year":"2025","unstructured":"Zeng Y, Qian P, Li G, Sun Y. Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study. World J Surg Oncol. 2025, 23:331. 10.1186\/s12957-025-03962-4","journal-title":"World J Surg Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1130734","article-title":"Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: a single-center retrospective study","volume":"13","author":"Liu CG","year":"2023","unstructured":"Liu CG, Li YF, Ma TY, et al.. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: a single-center retrospective study. Front Oncol. 2023, 13:1130734. 10.3389\/fonc.2023.1130734","journal-title":"Front Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03382-w","article-title":"Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis","volume":"22","author":"Xia LY","year":"2024","unstructured":"Xia LY, Cao XC, Yu Y. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis. World J Surg Oncol. 2024, 22:106. 10.1186\/s12957-024-03382-w","journal-title":"World J Surg Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1157789","article-title":"Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer","volume":"13","author":"Sanomachi T","year":"2023","unstructured":"Sanomachi T, Okuma HS, Kitadai R, et al.. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. Front Oncol. 2023, 13:1157789. 10.3389\/fonc.2023.1157789","journal-title":"Front Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906011","article-title":"Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience","volume":"12","author":"Xu H","year":"2022","unstructured":"Xu H, Han Y, Wu Y, et al.. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience. Front Oncol. 2022, 12:906011. 10.3389\/fonc.2022.906011","journal-title":"Front Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104127","article-title":"Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study","volume":"10","author":"Wu S","year":"2025","unstructured":"Wu S, Shang J, Li Z, et al.. Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study. ESMO Open. 2025, 10:104127. 10.1016\/j.esmoop.2024.104127","journal-title":"ESMO Open"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.29","article-title":"Improving HER2 testing reproducibility in HER2-low breast cancer","volume":"5","author":"Sajjadi E","year":"2022","unstructured":"Sajjadi E, Venetis K, Ivanova M, Fusco N. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist. 2022, 5:882-8. 10.20517\/cdr.2022.29","journal-title":"Cancer Drug Resist"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5152\/ejbh.2020.5809","article-title":"Lymph node ratio predicts long-term survival in lymph node-positive breast cancer","volume":"16","author":"Sakin A","year":"2020","unstructured":"Sakin A, Aldemir MN. Lymph node ratio predicts long-term survival in lymph node-positive breast cancer. Eur J Breast Health. 2020, 16:270-5. 10.5152\/ejbh.2020.5809","journal-title":"Eur J Breast Health"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2012.07.009","article-title":"Lymph node ratio and pN staging show different superiority as prognostic predictors depending on the number of lymph nodes dissected in Chinese patients with luminal A breast cancer","volume":"12","author":"Wang F","year":"2012","unstructured":"Wang F, He W, Qiu H, et al.. Lymph node ratio and pN staging show different superiority as prognostic predictors depending on the number of lymph nodes dissected in Chinese patients with luminal A breast cancer. Clin Breast Cancer. 2012, 12:404-11. 10.1016\/j.clbc.2012.07.009","journal-title":"Clin Breast Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526218-clinicopathological-features-and-prognostic-impact-of-human-epidermal-growth-factor-receptor-2-low-status-in-early-stage-breast-cancer-a-single-center-cohort-hormone-receptor-stratified-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:58:51Z","timestamp":1787306331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526218-clinicopathological-features-and-prognostic-impact-of-human-epidermal-growth-factor-receptor-2-low-status-in-early-stage-breast-cancer-a-single-center-cohort-hormone-receptor-stratified-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.114911","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}